#1Roche Roche and Genentech Company Presentation Pharma Partnering 2022#2The Roche Group A leading healthcare company dedicated to innovation in a sustainable way 1896 Founded in Basel, family still holds majority stake Lasting... >30 medicines on World Health Organization List of Essential Medicines #7 R&D investor in healthcare 62.8 bn Sales 2021 (CHF) 100,920 Employees worldwide 16,400,000 people treated worldwide with our medicines in 2021 Genentech1, first publicly-owned Biotech Roche and sustainable Among top companies in Dow Jones Sustainability Index (Life Sciences Sector) for 13 consecutive years 39 FDA Breakthrough Designations#3Our unique innovation model Providing scientific freedom to work, think and address problems in different ways RESEARCH AND EARLY DEVELOPMENT Genentech A Member of the Roche Grout Roche CHUGAI Roche A member of the Roche group: gRED PRED Chugai Independent Centers for Research and Early Development Spark THERAPEUTICS FOUNDATION MEDICINE LATE STAGE AND COMMERCIAL (PHARMA) Global Product Development Manufacturing Commercialization Worldwide Execution flatiron EXTERNAL INNOVATION ROCHE PHARMA PARTNERING | Managing over 250 partnerships Roche#4The leader in personalized healthcare Optimally positioning us for the future Leader in Diagnostics Combining pharmaceuticals and diagnostics under one roof together with deep know-how in molecular biology and data science, makes Roche a unique partner to drive the next step in the evolution of healthcare. Diagnosis Decision support Therapy Leader in Pharma Therapy monitoring Roche#5Global presence Pharma Partnering offices With around 120 people worldwide, Pharma Partnering offers speed, flexibility and accessibility to partners. South San Francisco Cambridge Basel Boston Tokyo Shanghai Roche#6Because a great idea is a great idea... ...no matter where it comes from Roche - 50% of R&D pipeline involve a partnership -40% SALECENSA alpodh MIRCERA aplyer stee GAZYVA HCMUBRA e-1-1 mth OCREVUS Esbriet prene capsle5230 VENCLEXTA VABYSHO COTELLIC Bes FASFRYNG ZELBORAF of total Pharma sales generated from partnered or in-licensed products ACTEMRA Tarceva susvimo Evrysdi GAVRETO RONAPREVE 13 ren Xolair Galicura ROZLYTREK Kadcyla Tarriflu CellCept cophenolate mofet RituxanHCELA Rituxan Bonviva Rituximab MabThera Envedo#7We make medicines for people with serious diseases Genentech Nutropin 1896 1976 Roche AVASTIN bevacizumab PERJETA perbumab VENCLEXTA www.ins PHESGO tentneembed DNEPRYNE Furysdi Roche Pulmozyme TNKase PEGASYS Nutropin NuSpin' Herceptin O Tarceva erlotinib &ACTEMRA Envedge T Esbriet lociliamule Mamodag www "TECENTRIQ xofluza GAVRETO *** VABYSMO 1987 1993 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2006 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 CellCept Rituxan ches to rat Rituximab Tamiflu Valcytes. 2020 2021 2022 Xolair Omakizamab LUCENTIS ZELBORAF Kadcyla (vemurafenibles 80-bentine SALECENSA alectinib OCREVUS ieman POLIVY RONAPREVE Got a cert GAZYVA obinutuzumab HEMLIBRA. COTELLIC S enicizumab ROZLYTREK susvimo" about#8Bringing early external innovation successfully to patients >2/3 of the partnered and launched medicines were partnered pre-clinical-Phase 1 Roche Dev. stage at deal signing Commercial Phase 3 Phase 2 Phase 1 Pre-Clinical Erivedge Kadcyla Tatum antar Deal nent stored Esbriet pirtenidone GAZYVA obinutuzumabece ☑COTELLIC VENCLEXTA vertod abst 2 OCREVUS acrelizumab xofluza ROZLYTREK (art GAVRETO psiseimb ENSPRYNG POLIVY Evrysdi. risdiplam RONAPREVE casiimat and mcevimat susvimo" ranibizumabinjection 3 VABYSMO Launch Year¹ 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 1 first launch in the US. 2 discovered under the research collaboration between Genentech and Abbott. 3 ANG2 binder from research collaboration with Affitech.#9Our approach to partnering in the pharma industry We value external innovation and bring our best experts to the table Roche OUR FOUR STEP PARTNERING PROCESS Identify the areas of interest Search for the latest developments Start the first conversations Ensure an enduring partnership#10We value external innovation Complementing our internal innovation and expertise AGREEMENTS ENTERED IN: Oncology Immunology 8 Product out-licensing agreements and divestments Ophthalmology Gene therapy Neurology Technology platforms PHC Rare diseases 9 Agreements derived from existing alliances 13 PHC agreements 1 Acquisition Roche 60 NEW AGREEMENTS in 2021 15 Product, technology or discovery license agreements 14 Research and discovery collaborations#11Get in touch with us! roche.com/partnering [email protected] Roche